医学
加药
伊克泽珠单抗
银屑病
银屑病面积及严重程度指数
不利影响
皮肤科生活质量指数
体表面积
内科学
塞库金单抗
皮肤病科
银屑病性关节炎
作者
Ying Li,Yingyuan Yu,Yutian Wang,Jiajing Lu,Xuemei Yi,Ning Yu,Yangfeng Ding,Yuling Shi
出处
期刊:European Journal of Dermatology
[John Libbey Eurotext]
日期:2022-09-01
卷期号:32 (5): 618-622
标识
DOI:10.1684/ejd.2022.4330
摘要
Little is known about different Ixekizumab (IXE) dosing regimens during routine clinical practice.To evaluate the real-world effectiveness and safety of different IXE dosing regimens in patients with psoriasis.This study retrospectively compared patients who were dosed with IXE every two or four weeks (80 mg/week following a starting dose of 160 mg at Week 0). At Weeks 0, 4, and 12, the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) were recorded, with adverse events also documented.In total, 66 patients were analysed, of whom 30 (45.5%) and 36 (54.5%) were included in the two-week and four-week IXE dosing groups, respectively. In the overall patient cohort, 86.3%, 60.6%, and 31.8% exhibited PASI 75, PASI, 90, and PASI 100 responses at Week 12, respectively. The mean baseline PASI score was 12.4±7.6 and the mean baseline DLQI score was 11.3±6.9, with these values declining rapidly following IXE administration to 1.6±2.4, and 2.6±4.0 at Week 12, respectively. Response rates were elevated in the two-week group as compared to the four-week group at Weeks 4 and 12 of treatment, but these differences were not significant. Adverse events were reported in 25 patients (37.9%), with injection site reactions being most common, followed by infections.IXE is effective and safe in a real-world setting for the treatment of plaque psoriasis. Moreover, patients can reduce their medical expenses by choosing a four-week dosing regimen while still attaining therapeutic benefits.
科研通智能强力驱动
Strongly Powered by AbleSci AI